Pharmaceutical Company BioDelivery Sciences International Inc continues to fall. The company’s stock lost $0.08 to close at $10.03. In a research note issued on Tuesday, analysts at Roth Capital dropped their objective on shares of the company from 18.00 to $16.00. The analysts have given a ‘buy’ rating on the stock. Currently, it looks like a very good potential purchase.

Target price of Roth Capital analysts would specify a potential upside of about 58.26% from the BioDelivery Sciences International’s current price. On Tuesday, the company traded down about 3.71%. The company has a 52 week low of $6.71, while its 52 week high was $18.48. The 50-day moving average of BioDelivery Sciences International’s stock was $14. In addition, the stock’s 200-day moving average was $14.

Currently, BioDelivery Sciences International has market cap of more than $528 million. On Monday, March 16, the company announced its earnings results. The company reports $0.51 earnings per share (EPS) for the quarter. EPS for the quarter missed the Thomson Reuters consensus estimate of $0.33. The company also stated that it had revenue of about $2.50 million for the quarter. The consensus estimate for the quarter was $4.00 million.

This year, BioDelivery Sciences International has many regulatory events, including a Food and Drug Administration (FDA) decision on Belbuca, a drug to treat moderate to severe pain. The regulatory events could benefit the company, whose stock is now down over 27% over the last five days.

BioDelivery Sciences International, Inc, is a specialty pharmaceutical company, which develops and commercializes applications of therapeutics to address medical needs. The company either develops applications of therapeutics on its own or in partnerships with third parties.